Search Results - "KIM, Esther"

Spontaneous Coronary-Artery Dissection by Kim, Esther S.H

“…Coronary-artery dissections account for less than 1% of acute myocardial infarctions, occur most commonly in women and most often between the ages of 47 and 53…”
Get full text

Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association by Hayes, Sharonne N, Kim, Esther S.H, Saw, Jacqueline, Adlam, David, Arslanian-Engoren, Cynthia, Economy, Katherine E, Ganesh, Santhi K, Gulati, Rajiv, Lindsay, Mark E, Mieres, Jennifer H, Naderi, Sahar, Shah, Svati, Thaler, David E, Tweet, Marysia S, Wood, Malissa J

“…Spontaneous coronary artery dissection (SCAD) has emerged as an important cause of acute coronary syndrome, myocardial infarction, and sudden death,…”
Get full text

Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes by Schauer, Philip R, Bhatt, Deepak L, Kirwan, John P, Wolski, Kathy, Brethauer, Stacy A, Navaneethan, Sankar D, Aminian, Ali, Pothier, Claire E, Kim, Esther S.H, Nissen, Steven E, Kashyap, Sangeeta R

“…At 3 years of follow-up, among obese patients with uncontrolled type 2 diabetes who were randomly assigned to receive intensive medical therapy with or without…”
Get full text

Enasidenib: First Global Approval by Kim, Esther S.

“…Enasidenib (Idhifa ® ) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios…”
Get full text

Olmutinib: First Global Approval by Kim, Esther S.

“…Olmutinib (Olita TM ) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer…”
Get full text

Avelumab: First Global Approval by Kim, Esther S.

“…Avelumab (Bavencio ® ) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the…”
Get full text

Abemaciclib: First Global Approval by Kim, Esther S.

“…Abemaciclib (Verzenio™) is an orally administered inhibitor of cyclin-dependent kinases 4 and 6 that is being developed by Eli Lilly and Company. Abemaciclib…”
Get full text

Midostaurin: First Global Approval by Kim, Esther S.

“…Midostaurin (Rydapt ® ) is a multikinase inhibitor being developed by Novartis Pharmaceuticals. In April 2017, midostaurin was approved in the USA for the…”
Get full text

Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review by Hayes, Sharonne N, Tweet, Marysia S, Adlam, David, Kim, Esther S H, Gulati, Rajiv, Price, Joel E, Rose, Carl H

“…Over the past decade, spontaneous coronary artery dissection (SCAD) has emerged as an important cause of myocardial infarction, particularly among younger…”
Get full text

Takayasu arteritis: challenges in diagnosis and management by Kim, Esther S H, Beckman, Joshua

“…Takayasu arteritis (TA) is a rare disease affecting chiefly young women, although it can affect both men and women and persons of many different ethnicities…”
Get more information

Letermovir: First Global Approval by Kim, Esther S.

“…Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc.,…”
Get full text

Lusutrombopag: First Global Approval by Kim, Esther S.

“…Lusutrombopag (Mulpleta ® ) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver…”
Get full text

Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography by Johri, Amer M., Nambi, Vijay, Naqvi, Tasneem Z., Feinstein, Steven B., Kim, Esther S.H., Park, Margaret M., Becher, Harald, Sillesen, Henrik

“…Atherosclerotic plaque detection by carotid ultrasound provides cardiovascular disease risk stratification. The advantages and disadvantages of two-dimensional…”
Get full text

Perfusion Assessment in Critical Limb Ischemia: Principles for Understanding and the Development of Evidence and Evaluation of Devices: A Scientific Statement From the American Heart Association by Misra, Sanjay, Shishehbor, Mehdi H, Takahashi, Edwin A, Aronow, Herbert D, Brewster, Luke P, Bunte, Matthew C, Kim, Esther S.H, Lindner, Jonathan R, Rich, Kathleen

“…There are >12 million patients with peripheral artery disease in the United States. The most severe form of peripheral artery disease is critical limb ischemia…”
Get full text

Dissection and Aneurysm in Patients With Fibromuscular Dysplasia: Findings From the U.S. Registry for FMD by Kadian-Dodov, Daniella, Gornik, Heather L, Gu, Xiaokui, Froehlich, James, Bacharach, J Michael, Chi, Yung-Wei, Gray, Bruce H, Jaff, Michael R, Kim, Esther S H, Mace, Pamela, Sharma, Aditya, Kline-Rogers, Eva, White, Christopher, Olin, Jeffrey W

“…Fibromuscular dysplasia (FMD) is a noninflammatory arterial disease that predominantly affects women. The arterial manifestations may include beading,…”
Get full text

The United States Registry for Fibromuscular Dysplasia: Results in the First 447 Patients by OLIN, Jeffrey W, FROEHLICH, James, MCBANE, Robert D, KLINE-ROGERS, Eva, WHITE, Christopher J, GORNIK, Heather L, XIAOKUI GU, BACHARACH, J. Michael, EAGLE, Kim, GRAY, Bruce H, JAFF, Michael R, KIM, Esther S. H, MACE, Pam, MATSUMOTO, Alan H

“…Fibromuscular dysplasia (FMD), a noninflammatory disease of medium-size arteries, may lead to stenosis, occlusion, dissection, and/or aneurysm. There has been…”
Get full text

Tivozanib: First Global Approval by Kim, Esther S.

“…Tivozanib (Fotivda ® ) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU,…”
Get full text

Diet Quality Indices and Postmenopausal Breast Cancer Survival by Kim, Esther H. J., Willett, Walter C., Fung, Teresa, Rosner, Bernard, Holmes, Michelle D.

“…Research on diet in breast cancer survival has been focused on single nutrients or foods, particularly dietary fat, fruits, vegetables, fiber, and alcohol. We…”
Get full text

First international consensus on the diagnosis and management of fibromuscular dysplasia by Gornik, Heather L, Persu, Alexandre, Adlam, David, Aparicio, Lucas S, Azizi, Michel, Boulanger, Marion, Bruno, Rosa M, De Leeuw, Peter, Fendrikova-Mahlay, Natalia, Froehlich, James, Ganesh, Santhi K, Gray, Bruce H, Jamison, Cathlin, Januszewicz, Andrzej, Jeunemaitre, Xavier, Kadian-Dodov, Daniella, Kim, Esther S H, Kovacic, Jason C, Mace, Pamela, Morganti, Alberto, Sharma, Aditya, Southerland, Andrew M, Touzé, Emmanuel, Van der Niepen, Patricia, Wang, Jiguang, Weinberg, Ido, Wilson, Scott, Olin, Jeffrey W, Plouin, Pierre-Francois

“…This article is a comprehensive document on the diagnosis and management of fibromuscular dysplasia (FMD) which was commissioned by the Working Group…”
Get full text

Surface composition of industrial spray-dried milk powders. 2. Effects of spray drying conditions on the surface composition by Kim, Esther H.-J., Chen, Xiao Dong, Pearce, David

“…The effects of various spray drying conditions (feed solids content, drying temperature, degree of homogenization and initial droplet size) on the surface…”
Get full text